Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

MEXILETINE HCL

All products: general benefit

Other products in the same Health Canada class (C01B) — coverage varies; not interchangeable

  • Amiodarone (Cordarone): general benefit, Not a benefit
  • Disopyramide (Norpace): general benefit, Not a benefit, Listing status unconfirmed
  • Flecainide (Tambocor): general benefit, Not a benefit
  • Propafenone (Rythmol): general benefit

Mint-Mexiletine · DIN 02536846 · 100mg · capsule

General benefitMarketed · checked 2026-09-19
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Mint-Mexiletine · DIN 02536846 Manufacturer: Mint Pharmaceuticals Inc.; listing date 2024-05-31 Health Canada: Marketed since 2024-04-08 · brand MINT-MEXILETINE · ATC C01BB02 MEXILETINE · form Capsule · route Oral · ingredients MEXILETINE HYDROCHLORIDE 100 MG · company Mint pharmaceuticals inc · schedule Prescription
Check this DIN again · Health Canada product record

Mint-Mexiletine: Formulary list price $0.7346/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.7346 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102557 · Verify on the e-Formulary ↗ (DIN 02536846)

Source record
DIN 02536846: Mint-Mexiletine Raw flags: chronicUseMed=Y, sec3=Y Item: 240400064; group id 285; item number 0609; lccId None; manufacturer id MIN Source form: Cap; strength: 100mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.7346; ministry $0.7346 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02536846 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102557
Interchangeable products
Mexitil · DIN 00599956 · not recorded Teva-Mexiletine · DIN 02230359 · $0.7346
Shortage status: not checked (no credentials)
Other drugs in the same formulary class (24:04 Cardiac Drugs) and how they are covered

Matched class: 24:04 Cardiac Drugs

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ATENOLOL, DIGOXIN, PROPAFENONE HCL Some products covered without a code (check the product listing): ACEBUTOLOL HCL, AMIODARONE HCL, AMLODIPINE, BISOPROLOL FUMARATE, DILTIAZEM HCL, DISOPYRAMIDE, FLECAINIDE ACETATE, METOPROLOL TARTRATE, NADOLOL, NIFEDIPINE, PROPRANOLOL, SOTALOL HCL, TIMOLOL MALEATE, VERAPAMIL HCL 24:00 CARDIOVASCULAR DRUGS

RANOLAZINE

· 2 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 500mg · ER Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 24:00 24:04 Cardiac Drugs

AMIODARONE HCL

· 9 products · Listed, not a benefit (1), General benefit (8) · strengths: 200mg · Tab

DISOPYRAMIDE

· 3 products · Listed, not a benefit (1), General benefit (1), Temporary benefit (1) · strengths: 100mg · Cap

FLECAINIDE ACETATE

· 14 products · Listed, not a benefit (2), General benefit (12) · strengths: 50mg, 100mg · Tab

PROPAFENONE HCL

· 6 products · General benefit · strengths: 150mg, 300mg · Tab

ACEBUTOLOL HCL

· 9 products · Listed, not a benefit (3), General benefit (6) · strengths: 100mg, 200mg, 400mg · Tab

AMLODIPINE

· 56 products · Limited Use, codes 645, 706 (1), Off-Formulary Interchangeable, not an ODB benefit (11), General benefit (44) · strengths: 1mg/mL, 2.5mg, 5mg, 10mg · Oral Sol, Tab

ATENOLOL

· 26 products · General benefit · strengths: 50mg, 100mg · Tab

BISOPROLOL FUMARATE

· 20 products · General benefit (18), Listed, not a benefit (2) · strengths: 1.25mg, 2.5mg, 5mg, 10mg · Tab

DIGOXIN

· 7 products · General benefit · strengths: 0.05mg/mL, 0.0625mg, 0.125mg · O/L, Tab

DILTIAZEM HCL

· 93 products · General benefit (91), Listed, not a benefit (2) · strengths: 120mg, 180mg, 240mg, 300mg, 360mg, 30mg, 60mg · ER Tab, LA Cap, SR Cap, Tab

METOPROLOL TARTRATE

· 28 products · Listed, not a benefit (6), General benefit (22) · strengths: 100mg, 200mg, 50mg · LA Tab, Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 24:04 and 9 more
Full class listing Related classes: 24:06 Antilipemic Drugs, 24:08 Hypotensive Drugs (For Diuretics See 40:28), 24:12 Vasodilating Drugs, 24:32 Renin-Angiotensin Aldosterone Inhibitors Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: documented life-threatening ventricular arrhythmias, documented symptomatic ventricular arrhythmias
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. Covered without a code on the Ontario formulary: PROPAFENONE HCL PROPAFENONE HCL · General benefit 1 INDICATIONS RYTHMOL® (propafenone hydrochloride) is indicated for:  the treatment of documented life-threatening ventricular arrhythmias, such as sustained ventricular tachycardia prevention. PM: https://pdf.hres.ca/dpd_pm/00062661.PDF; date August 26, 2021; DIN 00603708; fetched 2026-09-10 Product monograph RYTHMOL® may also be used for the treatment of patients with documented symptomatic ventricular arrhythmias when the symptoms are of sufficient severity to require treatment. PM: https://pdf.hres.ca/dpd_pm/00062661.PDF; date August 26, 2021; DIN 00603708; fetched 2026-09-10 Product monograph SOTALOL HCL · Listed, not a benefit (2), General benefit (8) APO-SOTALOL may also be used for the treatment of patients with documented symptomatic ventricular arrhythmias when the symptoms are of sufficient severity to require treatment. PM: https://pdf.hres.ca/dpd_pm/00066796.PDF; date July 22, 2022; DIN 02167794; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
1 INDICATIONS TEVA-MEXILETINE (mexiletine hydrochloride) is indicated for: • the treatment of documented life-threatening ventricular arrhythmias, such as sustained ventricular tachycardia. • the treatment of patients with documented symptomatic ventricular arrhythmias when the symptoms are of sufficient severity to require treatment. Because of the proarrhythmic effects of mexiletine, its use should be reserved for patients in whom, in the opinion of the physician, the benefit of treatment clearly outweighs the risks. 1.1 Pediatrics The safety and efficacy of mexiletine in children has not been established. Therefore, Health Canada has not authorized an indication for pediatric use. 1.2 Geriatrics No data are available. https://pdf.hres.ca/dpd_pm/00073596.PDF PM date: November 27, 2023 Source product: TEVA-MEXILETINE; DIN 02230359; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.